Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Healey, Jeff S.; Baranchuk, Adrian; Crystal, Eugene; Morillo, Carlos A.; Garfinkle, Michael; Yusuf, Salim; Connolly, Stuart J.

doi:10.1016/j.jacc.2004.11.070

Cited by 822Atrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmiasHeart Failure Treatment and Management

Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Open access

Healey, Jeff S., Baranchuk, Adrian, Crystal, Eugene, Morillo, Carlos A., Garfinkle, Michael, Yusuf, Salim, Connolly, Stuart J.·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2004.11.070

Open this paper in CoChat — free account Open PDF

Abstract

Objectives This study was designed to identify all randomized clinical trial data evaluating angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for the prevention of atrial fibrillation (AF), to estimate the magnitude of this effect and to identify patient subgroups most likely to benefit.Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduce morbidity and mortality in patients with heart failure, vascular disease, and hypertension. Several reports suggest that they may also prevent the development of AF.Methods A systematic review of the literature was performed to identify all reports of the effect of ACEIs or ARBs on the development of AF. Eligible studies had to be randomized, controlled, parallel-design human trials of an ACEI or ARB that collected data on the development of AF.Results A total of 11 studies, which included 56,308 patients, were identified: 4 in heart failure, 3 in hypertension, 2 in patients following cardioversion for AF, and 2 in patients following myocardial infarction. Overall, ACEIs and ARBs reduced the relative risk of AF by 28% (95% confidence interval [CI] 15% to 40%, p = 0.0002). Reduction in AF was similar between the two classes of drugs (ACEI: 28%, p = 0.01; ARB: 29%, p = 0.00002) and was greatest in patients with heart failure (relative risk reduction [RRR] = 44%, p = 0.007). Overall, there was no significant reduction in AF in patients with hypertension (RRR = 12%, p = 0.4), although one trial found a significant 29% reduction in patients with left ventricular (LV) hypertrophy. In patients following cardioversion, there appears to be a large effect (48% RRR), but the confidence limits are wide (95% CI 21% to 65%).Conclusions Both ACEIs and ARBs appear to be effective in the prevention of AF. This benefit appears to be limited to patients with systolic left ventricular dysfunction or LV hypertrophy. The use of these drugs following cardioversion appears promising but requires further study.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2004.11.070

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Retrospective analyses from large randomized trials have reported a lower incidence of new-onset AF in patients treated with ACE inhibitors/ARBs compared with placebo.
“Retrospective analyses from large randomized trials have reported a lower incidence of new-onset AF in patients treated with ACE inhibitors/ARBs compared with placebo.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [237]
ACE inhibitors or ARBs appear to prevent new-onset atrial fibrillation in patients with left ventricular dysfunction.
“ACE inhibitors or ARBs appear to prevent new-onset AF in patients with LV dysfunction and in hypertensive patients with LV hypertrophy.219,236,237,239,246,250,686”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [237]
ACE inhibitors or ARBs appear to prevent new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
“ACE inhibitors or ARBs appear to prevent new-onset AF in patients with LV dysfunction and in hypertensive patients with LV hypertrophy.219,236,237,239,246,250,686”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [237]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · see citing works
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664 · see citing works
Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407 · see citing works
Atrial Fibrillation Begets Atrial Fibrillation
WIJFFELS, M. C. E. F., Kirchhof, C. J. H. J., Dorland, R., & Allessie, M. A. (1995) · Circulation · doi:10.1161/01.cir.92.7.1954 · Cited by 3,500 · see citing works
Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort: The Framingham Heart Study
Benjamin, E. J. (1994) · JAMA · doi:10.1001/jama.1994.03510350050036 · Cited by 2,613 · see citing works
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604 · see citing works
Self-citation
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471 · see citing works
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14286-9 · Cited by 2,142 · see citing works
Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available.
Kannel, W. B., Wolf, P. A., Benjamin, E. J., & Levy, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00583-9 · Cited by 2,033 · see citing works
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
Hansson, L., Lindholm, L. H., NISKANEN, L. K., Lanke, J., Hedner, T., Niklason, A., LUOMANMÄKI, K., Dahlöf, B., Fairé, U. D., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 1,991 · see citing works
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials
Garg, R. (1995) · JAMA · doi:10.1001/jama.273.18.1450 · Cited by 1,773 · see citing works
A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Køber, L., Torp-Pedersen, C. T., Carlsen, J. E., Bagger, H., Eliasen, P., Lyngborg, K., Videbæk, J., Cole, D. S., Auclert, L., Pauly, N., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332503 · Cited by 1,768 · see citing works
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
Granger, C. B., McMurray, J. J., Yusuf, S., Held, P., Michelson, E. L., Olofsson, B., Östergren, J., Pfeffer, M. A., & Swedberg, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14284-5 · Cited by 1,686 · see citing works
Self-citation
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & Fairé, U. D. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,442 · see citing works
Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
Garg, R. (1995) · JAMA · doi:10.1001/jama.1995.03520420066040 · Cited by 1,395 · see citing works
Promotion of Atrial Fibrillation by Heart Failure in Dogs
Li, D., Fareh, S., Leung, T. K., & Nattel, S. (1999) · Circulation · doi:10.1161/01.cir.100.1.87 · Cited by 1,343 · see citing works
Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.
Vaziri, S. M., Larson, M. G., Benjamin, E. J., & Levy, D. (1994) · Circulation · doi:10.1161/01.cir.89.2.724 · Cited by 1,073 · see citing works
Chronic Rapid Atrial Pacing
Morillo, C. A., Klein, G. J., Jones, D. L., & Guiraudon, C. M. (1995) · Circulation · doi:10.1161/01.cir.91.5.1588 · Cited by 1,046 · see citing works
Self-citation
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826 · see citing works
Epidemiology and natural history of atrial fibrillation: clinical implications
Chugh, S. S., Blackshear, J. L., Shen, W.-K., Hammill, S. C., & Gersh, B. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01107-4 · Cited by 768 · see citing works
Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure
Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., & Nattel, S. (2001) · Circulation · doi:10.1161/hc4601.099402 · Cited by 702 · see citing works
Left Atrial Volume
Møller, J. E., Hillis, G. S., Oh, J. K., Seward, J. B., Reeder, G. S., Wright, R. S., Park, S. W., Bailey, K. R., & Pellikka, P. A. (2003) · Circulation · doi:10.1161/01.cir.0000066318.21784.43 · Cited by 690 · see citing works
Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study
Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685 · see citing works
Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventricular Dysfunction
Pedersen, O. D., Bagger, H., Køber, L., & Torp-Pedersen, C. T. (1999) · Circulation · doi:10.1161/01.cir.100.4.376 · Cited by 656 · see citing works
Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women
Tsang, T. S. M., Barnes, M. E., Bailey, K. R., Leibson, C. L., Montgomery, S. C., Takemoto, Y., Diamond, P. M., Marra, M. A., Gersh, B. J., Wiebers, D. O., et al. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.5.467 · Cited by 631 · see citing works
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
Weber, M. A., Julius, S., Kjeldsen, S. E., Brunner, H. R., Ekman, S., Hansson, L., Hua, T. A., Laragh, J. H., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16456-8 · Cited by 591 · see citing works
Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction
Vermès, E., Tardif, J., Bourassa, M. G., Racine, N., Lévesque, S., White, M., Guerra, P. G., & Ducharme, A. (2003) · Circulation · doi:10.1161/01.cir.0000072793.81076.d4 · Cited by 577 · see citing works
Effects of Atrial Dilatation on Refractory Period and Vulnerability to Atrial Fibrillation in the Isolated Langendorff-Perfused Rabbit Heart
Ravelli, F., & Allessie, M. A. (1997) · Circulation · doi:10.1161/01.cir.96.5.1686 · Cited by 478 · see citing works
Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation
Nakashima, H., Kumagai, K., Urata, H., Gondo, N., Ideishi, M., & Arakawa, K. (2000) · Circulation · doi:10.1161/01.cir.101.22.2612 · Cited by 443 · see citing works
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
The ONTARGET/TRANSCEND Investigators (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.020 · Cited by 381 · see citing works
Intra-Atrial Pressure Increases Rate and Organization of Waves Emanating From the Superior Pulmonary Veins During Atrial Fibrillation
Kalifa, J., Jalife, J., Зайцев, А. В., Bagwe, S., Warren, M. D., Moreno, J., Berenfeld, O., & Nattel, S. (2003) · Circulation · doi:10.1161/01.cir.0000086979.39843.7b · Cited by 342 · see citing works
Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study
Ueng, K. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.08.014 · Cited by 293 · see citing works
Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data
Pizzetti, F., Turazza, F. M., Franzosi, M. G., Barlera, S., Ledda, A., Maggioni, A. P., Santoro, L., & Tognoni, G. (2001) · Heart · doi:10.1136/heart.86.5.527 · Cited by 285 · see citing works
Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure
Shi, Y. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00243-2 · Cited by 237 · see citing works
Meta-analysis. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
Schmieder, R. E., Schlaich, M. P., Klingbeil, A. U., & Martus, P. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.3.564 · Cited by 190 · see citing works
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure
Cleland, J. G. F., Erhardt, L., Murray, G. D., Hall, A. S., & Ball, S. (1997) · European Heart Journal · doi:10.1093/eurheartj/18.1.41 · Cited by 186 · see citing works
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.
Cleland, J. G. F., Erhardt, L., Murray, G. D., et al. (1997) · PubMed · Cited by 168 · see citing works
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial
Granger, C. B., McMurray, J. J. V., & Yusuf, S. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.10.014 · Cited by 152 · see citing works
Self-citation
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
Pfeffer, M. A., McMurray, J. J. V., & Velazquez, E. J. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.12.039 · Cited by 146 · see citing works
Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation
Shi, Y. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00377-7 · Cited by 116 · see citing works
Effects of lisinopril in patients with heart failure and chronic atrial fibrillation
van den Berg, M. P., CRUNS, H. J. G. M., van Veldhuisen, D. J., Griep, N., de Kam, P. J., & Lie, K. I. (1995) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(05)80004-1 · Cited by 111 · see citing works
VErapamil Plus Antiarrhythmic drugs Reduce Atrial Fibrillation recurrences after an electrical cardioversion (VEPARAF Study)
Simone, A. D. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00311-7 · Cited by 75 · see citing works
Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction
Alsheikh-Ali, A. A. A., Wang, P. J., Rand, W., Konstam, M. A., Homoud, M. K., Link, M. S., Estes, N. A. M., Salem, D. N., & Al‐Ahmad, A. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.12.033 · Cited by 46 · see citing works
1145-122 Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM
Swedberg, K. B., Pfeffer, M. A., Solal, A. C., Ducharme, A., Granger, C. B., Michelson, E. L., McMurray, J. J. V., Young, J. D., & Yusuf, S. (2004) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(04)90941-2 · Cited by 32 · see citing works
Self-citation
Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study
Ueng, K.-C., Tsai, T. P., & Yu, W. C. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.03.015 · Cited by 26 · see citing works
Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study)
Simone, A. D., Pasquale, M. D., & Matteis, C. D. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.10.019 · Cited by 13 · see citing works
Enalapril treatment and hospitalization for atrial tachyarrhythmias in patients with left ventricular dysfunction
Alsheikh-Ali, A. A. A., Wang, P. J., Rand, W. M., et al. (2003) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(03)00431-7 · Cited by 6 · see citing works
Efectos del irbesartán sobre los canales de potasio responsables de la repolarización cardiaca humana
Fernández, J. I. M. (2005) · Dialnet (Universidad de la Rioja) · Cited by 2 · see citing works

Flagged first, then by citations

Research works printed but not linked: 2

Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 2002;106:331-6.
Kannel WB, Wolf PA, Benjamin EJ. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.

Sorted by citations

Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175 · see citing works
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036 · see citing works
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391 · see citing works
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333 · see citing works
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418 · see citing works
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347 · see citing works
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955 · see citing works
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): <i>Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society</i>
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805 · see citing works
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000040 · Cited by 2,056 · see citing works
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739 · see citing works
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403 · see citing works
Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications
Nattel, S., Burstein, B., & Dobrev, D. (2008) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.107.754564 · Cited by 1,124 · see citing works
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000596 · Cited by 1,127 · see citing works
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.017 · Cited by 933 · see citing works
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Kay, G. N., Le Huezey, J.-Y., Lowe, J. E., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214876d · Cited by 859 · see citing works
Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation: A Randomized Clinical Trial
Abed, H. S., Wittert, G. A., Leong, D. P., Shirazi, M. G., Bahrami, B., Middeldorp, M. E., Lorimer, M. F., Lau, D. H., Antic, N. A., Brooks, A. G., et al. (2013) · JAMA · doi:10.1001/jama.2013.280521 · Cited by 776 · see citing works
Valsartan for prevention of recurrent atrial fibrillation
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805710 · Cited by 441 · see citing works
Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure
Swedberg, K., Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Shi, H., Vincent, J., & Pitt, B. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.063 · Cited by 313 · see citing works
Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study
Marijon, E., Le Heuzey, J.-Y., Connolly, S., Yang, S., Pogue, J., Brueckmann, M., Eikelboom, J., Themeles, E., Ezekowitz, M., Wallentin, L., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000491 · Cited by 314 · see citing works
Self-citation
Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association
Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., et al. (2007) · Europace · doi:10.1093/europace/eum191 · Cited by 293 · see citing works
Management of atrial fibrillation
Lip, G. Y., & Tse, H.-F. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61300-2 · Cited by 229 · see citing works
Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’
Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp235 · Cited by 202 · see citing works
Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension
Manolis, A. J., Rosei, E. A., Coca, A., Cifkova, R., Erdine, S. E., Kjeldsen, S., Lip, G. Y. H., Narkiewicz, K., Parati, G., Redon, J., et al. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834f03bf · Cited by 198 · see citing works
Update on the Association of Inflammation and Atrial Fibrillation
PATEL, P., DOKAINISH, H., TSAI, P., & LAKKIS, N. (2010) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2010.01774.x · Cited by 190 · see citing works
Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial
Goette, A., Schön, N., Kirchhof, P., Breithardt, G., Fetsch, T., Häusler, K. G., Klein, H. U., Steinbeck, G., Wegscheider, K., & Meinertz, T. (2012) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.111.965178 · Cited by 187 · see citing works
Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis
Jibrini, M. B., Molnar, J., & Arora, R. R. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31804beb59 · Cited by 111 · see citing works
Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation: A Randomized, Open-Label Clinical Trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control])
Parkash, R., Wells, G. A., Sapp, J. L., Healey, J. S., Tardif, J.-C., Greiss, I., Rivard, L., Roux, J.-F., Gula, L., Nault, I., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026230 · Cited by 101 · see citing works
Self-citation

Inhibition of the expression of the gene for the angiotensin AT1 receptor by angiotensin II in the rat adrenal gland
Ishihata, A., Uno, S., Guo, D., et al. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00228-3 · Cited by 8 · see citing works
Effects of angiotensin analogues and angiotensin receptor antagonists on paraventricular neurones
Ambühl, P., Felix, D., Imboden, H., et al. (1992) · Regulatory Peptides · doi:10.1016/0167-0115(92)90049-z · Cited by 68 · see citing works
Effects of angiotensin II and its metabolites in the rat coronary vascular bed: Is angiotensin III the preferred ligand of the angiotensin AT2 receptor?
van Esch, J. H. M., Oosterveer, C. R., Batenburg, W. W., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.042 · Cited by 47 · see citing works
Two angiotensin II binding sites in rat brain revealed using [125I]Sar1, Ile8-angiotensin II and selective nonpeptide antagonists
Chang, R. S. L., Lotti, V. J., Chen, T., & Faust, K. A. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91218-h · Cited by 82 · see citing works
Des-aspartate-angiotensin I and angiotensin AT1 receptors in rat cardiac ventricles
Sim, M., & Min, L. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2005.02.002 · Cited by 4 · see citing works

Authors: Healey, J. S., Baranchuk, A., Crystal, E., Morillo, C. A., Garfinkle, M., Yusuf, S., & Connolly, S. J.
Affiliations: Population Health Research Institute (CA)
University of Toronto (CA)
Corresponding author: Healey, Jeff S.
ORCID: Healey, Jeff S.
Baranchuk, Adrian
Crystal, Eugene
Morillo, Carlos A.
Garfinkle, Michael
Yusuf, Salim
Connolly, Stuart J.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-06
Volume: 45
Issue: 11
Pages: 1832-1839
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2004.11.070
OpenAlex: W2111995867
Cited by: 822
References: 49
Citations by year: 2026: 12 · 2025: 17 · 2024: 21 · 2023: 23 · 2022: 17 · 2021: 16 · 2020: 20 · 2019: 19 · 2018: 27 · 2017: 29 · 2016: 25 · 2015: 26 · 2014: 39 · 2013: 45 · 2012: 51
FWCI: 12.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2967 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: atrial fibrillation, ACE inhibitors, angiotensin receptor blockers, atrial fibrillation prevention, heart failure, hypertension, left ventricular hypertrophy, left ventricular dysfunction, cardioversion, myocardial infarction
MeSH terms: Angiotensin-Converting Enzyme Inhibitors, Atrial Fibrillation, Electric Countershock, Humans, Comorbidity, Randomized Controlled Trials as Topic, Hypertrophy, Left Ventricular, Ventricular Dysfunction, Left, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks